Avadel Pharmaceuticals plc Quarterly Income Statements Chart
Quarterly
|
Annual
Avadel Pharmaceuticals plc Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| net product revenue | 19,453,000 | 7,014,000 | 1,496,000 | 10,091,000 | 12,243,000 | 10,995,000 | 14,229,000 | 17,554,000 | 16,437,000 | 19,320,000 | 19,826,000 | 29,116,000 | 33,161,000 | ||||||||||||||
| yoy | -42.51% | -25.52% | -43.09% | -28.23% | -39.71% | -50.43% | |||||||||||||||||||||
| qoq | 177.35% | 368.85% | -17.58% | 11.35% | -22.73% | -18.94% | 6.80% | -14.92% | -2.55% | -31.91% | -12.20% | ||||||||||||||||
| cost of products sold | 693,000 | 117,000 | 36,000 | 3,285,000 | 2,457,000 | 2,414,000 | 2,823,000 | 3,622,000 | 3,266,000 | 4,292,000 | 3,120,000 | 3,512,000 | 6,592,000 | ||||||||||||||
| gross profit | 18,760,000 | 6,897,000 | 1,460,000 | ||||||||||||||||||||||||
| yoy | |||||||||||||||||||||||||||
| qoq | 172.00% | 372.40% | |||||||||||||||||||||||||
| gross margin % | 96.44% | 98.33% | 97.59% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||
| research and development expenses | 2,359,000 | 2,849,000 | 4,223,000 | 4,380,000 | 6,762,000 | 3,852,000 | 5,286,000 | 5,569,000 | 4,057,000 | 5,530,000 | 7,757,000 | 7,539,000 | 10,292,000 | 7,329,000 | 6,086,000 | 11,402,000 | 11,890,000 | 9,951,000 | 11,325,000 | 8,095,000 | 6,792,000 | 7,206,000 | 5,283,750 | 8,143,000 | 7,604,000 | 5,388,000 | |
| selling, general and administrative expenses | 41,301,000 | 39,158,000 | 46,778,000 | 21,283,000 | 15,174,000 | 11,012,000 | 8,974,000 | 8,423,000 | 7,095,000 | 7,913,000 | 7,663,000 | 5,316,000 | 6,758,000 | 10,446,000 | 23,200,000 | 24,829,000 | 27,843,000 | 24,487,000 | 23,056,000 | 11,563,000 | 12,429,000 | 11,812,000 | 8,372,750 | 12,740,000 | 11,290,000 | 9,461,000 | |
| restructuring income | |||||||||||||||||||||||||||
| total operating expense | 30,326,500 | 42,007,000 | 51,001,000 | 25,663,000 | 14,811,000 | 564,750 | 13,697,000 | ||||||||||||||||||||
| operating income | -24,900,000 | -35,110,000 | -49,541,000 | -25,663,000 | -21,936,000 | -14,811,000 | -14,260,000 | -13,697,000 | 40,269,000 | -6,497,000 | -7,347,000 | -4,147,000 | -4,451,000 | -8,167,000 | -75,421,000 | -14,095,000 | -2,785,000 | -12,625,000 | -4,080,000 | 26,118,000 | 34,126,000 | 33,341,000 | 17,064,000 | -16,190,000 | -11,543,000 | 5,542,000 | |
| yoy | 13.51% | 137.05% | 247.41% | 87.36% | -154.47% | 127.97% | 94.09% | 230.29% | -1004.72% | -20.45% | -90.26% | -70.58% | 59.82% | -35.31% | 1748.55% | -153.97% | -108.16% | -137.87% | -123.91% | -261.32% | -395.64% | 501.61% | |||||
| qoq | -29.08% | -29.13% | 93.04% | 16.99% | 48.11% | 3.86% | 4.11% | -134.01% | -719.81% | -11.57% | 77.16% | -6.83% | -45.50% | -89.17% | 435.09% | 406.10% | -77.94% | 209.44% | -115.62% | -23.47% | 2.35% | 95.39% | -205.40% | 40.26% | -308.28% | ||
| operating margin % | -128.00% | -500.57% | -3311.56% | 399.06% | -53.07% | -66.82% | -29.14% | -25.36% | -49.69% | -390.38% | -71.09% | -9.57% | -38.07% | ||||||||||||||
| investment and other income | -1,632,000 | 903,000 | 623,000 | 489,000 | 432,000 | 610,000 | 74,000 | 213,000 | -741,000 | -378,000 | -1,479,000 | 781,000 | 950,000 | 817,000 | -393,000 | 208,000 | 583,000 | ||||||||||
| interest expense | -2,354,000 | -1,978,000 | -2,295,000 | -1,929,000 | -1,930,000 | -1,929,000 | -3,308,000 | -3,259,000 | -3,237,000 | -3,190,000 | -3,190,000 | -3,125,000 | -3,106,000 | -3,062,000 | -3,045,000 | -3,000,000 | -2,980,000 | -1,597,000 | -263,000 | -263,000 | -263,000 | -263,000 | -261,000 | -264,000 | -263,000 | -175,000 | |
| loss on extinguishment of debt | -13,129,000 | ||||||||||||||||||||||||||
| income before income taxes | -28,886,000 | -36,185,000 | -64,342,000 | -27,103,000 | -23,346,000 | -16,052,000 | -14,130,000 | -16,743,000 | 36,166,000 | -10,375,000 | -11,736,000 | -6,630,000 | -6,824,000 | -13,392,000 | -78,392,000 | -16,462,000 | -3,780,000 | -14,563,000 | -5,686,000 | 27,600,000 | 36,297,000 | 34,449,000 | 18,080,000 | -16,543,000 | -12,509,000 | 765,000 | |
| income tax benefit | -100,000 | 89,000 | 90,000 | -5,101,000 | -2,607,000 | -2,852,000 | -5,040,000 | 5,292,000 | -9,510,000 | -8,997,000 | 2,234,000 | 1,781,000 | -374,000 | -14,533,000 | -691,000 | -342,000 | -2,327,000 | ||||||||||
| net income | -28,786,000 | -36,274,000 | -64,432,000 | -22,002,000 | -19,581,000 | -13,445,000 | -11,278,000 | -11,703,000 | 30,874,000 | -865,000 | -2,739,000 | -8,864,000 | -8,605,000 | -13,018,000 | -63,859,000 | -15,771,000 | -3,438,000 | -12,236,000 | -8,245,000 | 21,679,000 | 28,927,000 | 25,910,000 | 4,734,000 | -19,994,000 | -19,958,000 | -6,376,000 | |
| yoy | 47.01% | 169.80% | 471.31% | 88.00% | -163.42% | 1454.34% | 311.76% | 32.03% | -458.79% | -93.36% | -95.71% | -43.80% | 150.29% | 6.39% | 674.52% | -172.75% | -111.89% | -147.23% | -274.17% | -208.43% | -244.94% | -506.37% | |||||
| qoq | -20.64% | -43.70% | 192.85% | 12.36% | 45.64% | 19.21% | -3.63% | -137.91% | -3669.25% | -68.42% | -69.10% | 3.01% | -33.90% | -79.61% | 304.91% | 358.73% | -71.90% | 48.41% | -138.03% | -25.06% | 11.64% | 447.32% | -123.68% | 0.18% | 213.02% | ||
| net income margin % | -147.98% | -517.17% | -4306.95% | 305.96% | -7.07% | -24.91% | -62.30% | -49.02% | -79.20% | -330.53% | -79.55% | -11.81% | -36.90% | ||||||||||||||
| net income per share | -0.29 | -0.41 | -0.83 | -0.38 | -0.33 | -0.23 | -0.23 | -0.2 | 0.57 | -0.02 | -0.07 | -0.24 | -0.23 | -0.35 | -1.71 | -0.43 | -0.09 | -0.32 | -0.18 | 0.54 | 0.7 | 0.63 | -0.28 | -0.48 | -0.48 | -0.15 | |
| weighted-average number of shares outstanding - basic | 80,174 | 89,380 | 77,246 | 58,585 | 58,488 | 58,443 | 52,996 | 58,213 | 54,272 | 41,057 | 37,403 | 37,436 | 37,356 | 37,354 | 37,325 | 36,904 | 36,772 | 38,559 | 40,465 | 40,061 | 41,091 | 41,374 | 41,248 | 41,241 | 41,241 | 41,241 | |
| weighted-average number of shares outstanding - diluted | 80,174 | 89,380 | 77,246 | 58,585 | 58,488 | 58,443 | 54,941 | 58,213 | 69,942 | 41,057 | 37,403 | 37,436 | 37,356 | 37,354 | 37,325 | 36,904 | 36,772 | 38,559 | 41,765 | 41,339 | 42,487 | 42,810 | 41,248 | 41,241 | 41,241 | 41,241 | |
| restructuring expense | |||||||||||||||||||||||||||
| intangible asset amortization | 203,000 | 203,000 | 206,000 | 205,000 | 204,000 | 201,000 | 1,623,000 | 1,620,000 | 1,609,000 | 1,767,000 | 1,967,000 | 564,000 | 564,000 | 564,000 | 2,970,000 | 3,702,000 | 3,702,000 | 3,514,000 | |||||||||
| changes in fair value of contingent consideration | -69,000 | 918,000 | 2,478,000 | ||||||||||||||||||||||||
| gain on sale of hospital products | |||||||||||||||||||||||||||
| gain from release of certain liabilities | 88,000 | 78,000 | |||||||||||||||||||||||||
| other income - changes in fair value of contingent consideration payable | -125,000 | -310,000 | |||||||||||||||||||||||||
| restructuring costs | 24,000 | 159,000 | 1,841,000 | 1,866,000 | 1,506,000 | 1,228,000 | 748,000 | 65,000 | 50,000 | 153,000 | 1,069,000 | 2,653,000 | |||||||||||||||
| total operating income | 21,936,000 | -30,178,000 | |||||||||||||||||||||||||
| income tax (benefit) expense | -3,765,000 | ||||||||||||||||||||||||||
| restructuring (income) costs | -53,000 | -226,000 | 793,250 | -549,000 | |||||||||||||||||||||||
| loss on deconsolidation of subsidiary | 162,000 | -167,000 | -2,673,000 | ||||||||||||||||||||||||
| gain on sale of hospital business | -45,760,000 | ||||||||||||||||||||||||||
| total operating expenses | 18,740,000 | 18,342,000 | 18,376,000 | 22,005,000 | 24,604,000 | 96,341,000 | 33,921,000 | 32,015,000 | 45,918,000 | 38,832,000 | 13,557,000 | 12,185,000 | 19,166,000 | ||||||||||||||
| revenues: | |||||||||||||||||||||||||||
| license revenue | 1,600,000 | 114,000 | 132,000 | ||||||||||||||||||||||||
| total revenues | 10,995,000 | 14,229,000 | 17,554,000 | 16,437,000 | 20,920,000 | 19,826,000 | 29,230,000 | 33,293,000 | |||||||||||||||||||
| changes in fair value of related party contingent consideration | -1,539,000 | 627,000 | -377,000 | 2,134,000 | -13,230,000 | -6,971,000 | -3,704,000 | 20,848,000 | 23,898,000 | ||||||||||||||||||
| other income - changes in fair value of related party payable | 118,000 | -139,000 | -50,000 | -307,000 | 467,000 | 425,000 | 1,402,000 | -395,000 | -917,000 | 768,000 | 1,670,000 | 550,000 | -413,000 | -1,828,000 | -2,773,000 | ||||||||||||
| gain - changes in fair value of related party contingent consideration | -4,259,000 | -7,115,000 | -12,889,000 | 2,968,000 | |||||||||||||||||||||||
| investment income and other income | 54,000 | ||||||||||||||||||||||||||
| product sales and services | 34,832,000 | 39,147,000 | 47,105,000 | 51,757,000 | 42,364,000 | 31,340,000 | 38,165,000 | 35,353,000 | |||||||||||||||||||
| license and research revenue | -80,000 | 528,000 | -794,000 | 750,000 | 721,000 | 747,000 | 693,000 | 863,000 | |||||||||||||||||||
| total | 34,623,250 | 39,675,000 | 46,311,000 | 52,507,000 | 43,085,000 | 32,087,000 | 38,858,000 | 36,216,000 | |||||||||||||||||||
| cost of products and services sold | 4,048,000 | 3,790,000 | 4,561,000 | 3,902,000 | 2,591,000 | 2,844,000 | 3,907,000 | 4,395,000 | |||||||||||||||||||
| (gain)/loss - changes in fair value of related party contingent consideration | -7,526,750 | -9,906,000 | |||||||||||||||||||||||||
| investment income | 161,000 | 1,110,000 | 527,000 | 1,052,000 | 270,000 | 490,000 | 390,000 | 200,000 | |||||||||||||||||||
| foreign exchange gain | -587,000 | -133,000 | 237,000 | 1,135,000 | 1,249,000 | 1,680,000 | -2,941,000 | ||||||||||||||||||||
| income tax provision | 2,559,000 | 5,921,000 | 7,370,000 | 8,539,000 | 4,553,000 | 3,451,000 | 7,449,000 | 7,141,000 | |||||||||||||||||||
| foreign exchange loss | -231,000 | ||||||||||||||||||||||||||
| changes in fair value of related party acquisition-related contingent consideration | 7,916,000 | ||||||||||||||||||||||||||
| interest expense - changes in fair value of related party financing-related contingent consideration | -1,861,000 |
We provide you with 20 years income statements for Avadel Pharmaceuticals plc stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Avadel Pharmaceuticals plc stock. Explore the full financial landscape of Avadel Pharmaceuticals plc stock with our expertly curated income statements.
The information provided in this report about Avadel Pharmaceuticals plc stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.